Genetic TestingGenetic Testing

Genetic Testing

Understanding Chromosomal Changes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Cells1

CLL/SLL cells can have chromosomal deletions (part of a chromosome lost or deleted), gene mutations (change), or a combination of both.

Parts of a chromosome can be lost (deleted) during cell division. Chromosomal deletions are named “del” for “deletion” followed by the name of the missing piece. 

Genes can become mutated. Some mutations may cause cancer, but not all mutations are dangerous.

Expand All

Chromosomal deletions1

Parts of a chromosome can be lost (deleted) during cell division. Chromosomal deletions are named “del” for “deletion” followed by the name of the missing piece. 

Gene mutations1

Genes can become mutated. Some mutations may cause cancer, but not all mutations are dangerous.

Gene mutations and chromosomal deletions can affect how CLL/SLL progresses and may help doctors develop your treatment plan.
 

How will my doctor know about chromosomal abnormalities in my CLL/SLL cells?1

Genetic testing can give your doctor important information about how your condition may progress over time. It can also help inform treatment decisions. Tests are done using blood, bone marrow, or tissue samples. One of the tests that searches for chromosomal deletions is FISH. FISH stands for “fluorescence in situ hybridization.” A different lab test, called DNA sequencing, examines CLL/SLL cells for gene mutations. It can identify the mutational status of IGHV (immunoglobulin heavy-chain variable region gene) and other genes.

What do my test results mean?1,2

Your test results may help you and your doctor better understand your disease. Up to 50% of patients with CLL/SLL have a sign of high-risk disease that can inform how their disease will progress. To learn more about genetic testing, contact your doctor.

Some genetic risk factors for CLL/SLL include:
 

CLL/SLL may be more aggressive in people with this chromosomal deletion compared to those with a complete chromosome.

Among people with CLL/SLL who have not had any treatment, about 3% to 10% have the 17p chromosome deletion. Del 17p can become more common as CLL progresses. 

Another chromosomal deletion that can mean that CLL/SLL may be more aggressive in people who have the deletion than in those with a complete chromosome. 

About 1 in 5 people with CLL have 11q deletion. 

The unmutated IGHV gene is a risk factor linked to more aggressive diseases.

Approximately 40% of people with CLL have unmutated IGHV.

Expand All

Del 17p1,3,4

CLL/SLL may be more aggressive in people with this chromosomal deletion compared to those with a complete chromosome.

Among people with CLL/SLL who have not had any treatment, about 3% to 10% have the 17p chromosome deletion. Del 17p can become more common as CLL progresses. 

Del 11q1,2

Another chromosomal deletion that can mean that CLL/SLL may be more aggressive in people who have the deletion than in those with a complete chromosome. 

About 1 in 5 people with CLL have 11q deletion. 

Unmutated IGHV 1,3,5

The unmutated IGHV gene is a risk factor linked to more aggressive diseases.

Approximately 40% of people with CLL have unmutated IGHV.

References: 1Leukemia and Lymphoma Society. The CLL Guide: Information for patients and caregivers. Chronic lymphocytic leukemia. Revised June 2021. Accessed May 9, 2023. https://www.lls.org/sites/default/files/2021-07/PS34_CLL_Booklet_2021.pdf 2Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89(7):2516-2522. 3Lee J, Wang YL. Prognostic and predictive molecular biomarkers in chronic lymphocytic leukemia. J Mol Diagn. 2020;22(9): 1114-1125. 4Schnaiter A, Stilgenbauer S. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach. Hematol Oncol Clin North Am. 2013;27(2):289-301. 5Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.

Pharmacyclics, an AbbVie Company, may collect your personal data through your online and offline interactions with us, including your contact, demographic, geolocation, and health-related data. We may also collect your online usage data automatically through cookies and similar technologies. We use this data for several purposes, such as to provide you with and improve our programs, services, and products, customize your experiences, and for research and analytics. We retain your personal data for as long as necessary to fulfill these purposes or to comply with our record retention obligations. We do not sell your personal data but may use and disclose your personal data with marketing and advertising partners to deliver you ads based on your interests inferred from your activity across other unaffiliated sites and services (“online targeted advertising”) and for website analytics. To opt out of the use or disclosure of your personal data for online targeted advertising or for website analytics, go to Your Privacy Choices on our website. For more information on the personal data categories we collect, the purposes for their collection, our disclosures to third parties, your data subject rights, and our data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose Personal Data section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at
https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).